Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

5.10USD
17 Aug 2018
Change (% chg)

$-0.05 (-0.97%)
Prev Close
$5.15
Open
$5.15
Day's High
$5.15
Day's Low
$5.05
Volume
3,700
Avg. Vol
12,575
52-wk High
$13.30
52-wk Low
$4.25

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 2.25
Market Cap(Mil.): $88.31
Shares Outstanding(Mil.): 13.52
Dividend: --
Yield (%): --

Financials

  TRIL.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -4.21 -- --
ROI: -60.97 2.89 12.63
ROE: -256.20 1.65 14.82

BRIEF-Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Co's Common Shares By Selling Shareholders

* TRILLIUM THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF 2.35 MILLION CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2IoCJmp) Further company coverage:

May 16 2018

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

Apr 10 2018

BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

* TRILLIUM THERAPEUTICS' TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

Mar 20 2018

BRIEF-Trillium Therapeutics Reports Annual 2017 Financial And Operating Results

* TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS

Mar 09 2018

Earnings vs. Estimates